Pharmarise Holdings Corp. (2796) AI Stock Analysis

• Market Cap: ¥6.09B
• Dividend Yield: 2.65%
• Average Volume (3M): 15.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.21
• Revenue Growth: 15.66%
• EPS Growth: 56.93%
• Country: JP
• Employees: 1,848
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 11.37
• Shares Outstanding: 12,060,381
• 10 Day Avg. Volume: 9,170
• 30 Day Avg. Volume: 15,546
• PEG Ratio: 5.37
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 0.09
• P/FCF Ratio: 9.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: ¥551.00 ▲(5.76% Upside)

Pharmarise Holdings Corp. receives a moderate score due to strong cash flow generation and positive technical indicators, despite challenges in profitability and valuation concerns. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

The company's moderate revenue growth indicates a solid market position and ability to expand its customer base, supporting long-term business sustainability.

Cash Flow Generation

Strong cash flow growth enhances financial flexibility, allowing for reinvestment in R&D and strategic initiatives, crucial for long-term competitiveness.

Product Diversification

A diversified product portfolio reduces dependency on a single revenue stream, mitigating risks and enhancing resilience against market fluctuations.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk during economic downturns, potentially impacting long-term growth and stability.

Profitability Challenges

Ongoing profitability issues may hinder the company's ability to reinvest in growth and innovation, affecting its competitive position over time.

Negative Return on Equity

Inefficient use of equity capital can undermine investor confidence and limit the company's ability to attract new investments, impacting future growth.

Pharmarise Holdings Corp. Business Overview & Revenue Model

Company Description

Pharmarise Holdings Corporation manages dispensing pharmacies in Japan. Its dispensing pharmacies provide patients with dispensing services based on prescriptions drawn up by medical institutions. The company also manages drug stores and convenience stores; and sells cosmetics. In addition, it is involved in the storage and management of medical examination records of patients on behalf of medical institutions; operation of medical mall; and provision of temporary help. As of May 31, 2021, the company operated 347 stores. Pharmarise Holdings Corporation was incorporated in 1984 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Pharmarise Holdings Corp. generates revenue primarily through the sale of its pharmaceutical products, including both prescription medications and over-the-counter drugs. The company's revenue model includes direct sales to healthcare providers, hospitals, and pharmacies, as well as partnerships with larger pharmaceutical firms for distribution and co-marketing agreements. Additionally, Pharmarise may earn revenue through licensing agreements for its proprietary drug formulations, royalties from patent holders, and government grants for research and development initiatives. Key partnerships with research institutions and global pharmaceutical companies further enhance its earnings potential by facilitating access to new markets and sharing the costs associated with drug development.

Pharmarise Holdings Corp. Financial Statement Overview

Summary

Pharmarise Holdings Corp. shows moderate revenue growth and strong cash flow generation, but faces challenges in profitability and high leverage. The company needs to improve operational efficiency and manage costs better.

Income Statement

Pharmarise Holdings Corp. has shown moderate revenue growth with a 5.2% increase in the latest year. However, the company is struggling with profitability, as indicated by a negative net income and declining EBIT margins. The gross profit margin remains stable, but the net profit margin is negative, highlighting challenges in cost management and operational efficiency.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of approximately 2.08, indicating a relatively high leverage. The equity ratio is stable, suggesting a balanced asset structure. However, the negative return on equity indicates inefficiencies in generating returns from shareholders' investments.

Cash Flow

Cash flow analysis shows a strong free cash flow growth rate of 74.2%, indicating improved cash generation capabilities. The operating cash flow to net income ratio is positive, suggesting effective cash conversion despite negative net income. However, the free cash flow to net income ratio is below 1, indicating potential challenges in sustaining cash flow levels.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.03B	63.51B	54.47B	52.03B	51.61B	52.32B
Gross Profit	8.66B	8.96B	8.45B	8.13B	8.12B	8.07B
EBITDA	1.75B	1.68B	1.38B	2.33B	2.69B	2.62B
Net Income	-255.00M	-367.00M	-351.00M	333.00M	447.00M	426.00M
Balance Sheet
Total Assets	30.17B	31.92B	29.49B	23.42B	23.75B	24.72B
Cash, Cash Equivalents and Short-Term Investments	2.12B	4.92B	7.15B	4.74B	3.99B	4.60B
Total Debt	13.03B	14.28B	12.75B	9.14B	9.91B	10.70B
Total Liabilities	23.54B	25.01B	22.05B	16.43B	17.05B	18.39B
Stockholders Equity	6.62B	6.87B	7.36B	6.88B	6.61B	6.22B
Cash Flow
Free Cash Flow	0.00	609.00M	2.10B	1.98B	247.00M	1.39B
Operating Cash Flow	0.00	1.31B	2.71B	2.52B	713.00M	1.95B
Investing Cash Flow	0.00	-4.46B	-3.12B	-703.00M	-292.00M	-1.08B
Financing Cash Flow	0.00	939.00M	2.77B	-1.07B	-1.03B	-728.00M

Pharmarise Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 521.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2796, the sentiment is Negative. The current price of 521 is above the 20-day moving average (MA) of 520.70, below the 50-day MA of 522.86, and above the 200-day MA of 505.63, indicating a neutral trend. The MACD of -0.32 indicates Negative momentum. The RSI at 46.11 is Neutral, neither overbought nor oversold. The STOCH value of 51.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2796.

Pharmarise Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3417	73 Outperform	¥19.96B	6.97	―	1.83%	4.30%	52.38%
4350	70 Outperform	¥15.69B	10.09	―	2.32%	6.60%	27.97%
3544	67 Neutral	¥11.91B	21.89	―	1.24%	3.58%	-10.70%
7679	66 Neutral	¥39.62B	9.15	―	1.29%	7.12%	14.14%
2796	60 Neutral	¥6.09B	-41.10	―	2.65%	15.66%	56.93%
8095	58 Neutral	¥19.28B	8.81	―	3.73%	15.00%	-195.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%